A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
Stopped Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study
Conditions
- Metastatic Castration Resistant Prostate Cancer
Interventions
Sponsor
Accutar Biotechnology Inc